{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T06:57:51Z","timestamp":1793429871847,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T00:00:00Z","timestamp":1583366400000},"content-version":"vor","delay-in-days":33,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007816","name":"Alcon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007816","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biocad"},{"name":"Kemin"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ophthalmos"},{"name":"Alcon, Phelcom"},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.clinthera.2019.12.008","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T03:15:38Z","timestamp":1582254938000},"page":"263-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Fixed-combination Bimatoprost\/Brimonidine\/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil\u2606"],"prefix":"10.1016","volume":"42","author":[{"suffix":"Jr.","given":"Rubens","family":"Belfort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayter Silva","family":"Paula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Jord\u00e3o","family":"Lopes Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Della Paolera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margot L.","family":"Goodkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.12.008_bib1","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","article-title":"Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial","volume":"120","author":"Heijl","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archopht.121.1.48","article-title":"Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial","volume":"121","author":"Leske","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib3","doi-asserted-by":"crossref","unstructured":"European Glaucoma Society. Terminology and Guidelines for Glaucoma (4th ed.). Available at: https:\/\/bjo.bmj.com\/content\/bjophthalmol\/101\/4\/1.full.pdf. Accessed January 11, 2020.","DOI":"10.1136\/bjophthalmol-2016-EGSguideline.001"},{"key":"10.1016\/j.clinthera.2019.12.008_bib4","unstructured":"American Academy of Ophthalmology. Preferred Practice Patterns\u2014Primary Open-Angle Glaucoma. Available at: http:\/\/www.aaojournal.org\/article\/S0161-6420(15)01276-2\/pdf. Accessed January 11, 2020."},{"key":"10.1016\/j.clinthera.2019.12.008_bib5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","article-title":"The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma","volume":"120","author":"Kass","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib6","unstructured":"Allergan plc. Alphagan P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15% [prescribing information]. Available at: http:\/\/www.allergan.com\/assets\/pdf\/alphaganp_pi.pdf. Accessed January 11, 2020."},{"key":"10.1016\/j.clinthera.2019.12.008_bib7","unstructured":"Allergan plc. Lumigan (bimatoprost ophthalmic solution) 0.01% [prescribing information]. Available at: http:\/\/www.allergan.com\/assets\/pdf\/lumigan_pi.pdf. Accessed January 11, 2020."},{"key":"10.1016\/j.clinthera.2019.12.008_bib8","unstructured":"Bausch\u00a0+ Lomb. Timoptic 0.25% and 0.5% (timolol maleate ophthalmic solution). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/018086s076lbl.pdf. Accessed January 11, 2020."},{"key":"10.1016\/j.clinthera.2019.12.008_bib9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/jop.2005.21.337","article-title":"Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension","volume":"21","author":"Craven","year":"2005","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2019.12.008_bib10","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/archopht.124.9.1230","article-title":"Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial","volume":"124","author":"Sherwood","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib11","first-page":"1","article-title":"Considerations in glaucoma therapy: fixed combinations versus their component medications","volume":"4","author":"Higginbotham","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib12","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/IJG.0b013e3181bdb586","article-title":"The safety and efficacy of bimatoprost\/timolol fixed combination: a 1-year double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension","volume":"19","author":"Lewis","year":"2010","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.clinthera.2019.12.008_bib13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ajo.2010.07.024","article-title":"Control of intraocular pressure and fluctuation with fixed-combination brimonidine-timolol versus brimonidine or timolol monotherapy","volume":"151","author":"Spaeth","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib14","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/eye.2013.83","article-title":"Fixed-combination brinzolamide 1%\/brimonidine 0.2% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies","volume":"27","author":"Realini","year":"2013","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.clinthera.2019.12.008_bib15","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1517\/14656566.2014.936850","article-title":"Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice","volume":"15","author":"Hollo","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2019.12.008_bib16","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2147\/OPTH.S55590","article-title":"Safety and efficacy of a fixed versus unfixed brinzolamide\/timolol combination in Japanese patients with open-angle glaucoma or ocular hypertension","volume":"8","author":"Nagayama","year":"2014","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1089\/jop.2012.0186","article-title":"Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis","volume":"29","author":"Quaranta","year":"2013","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2019.12.008_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ajo.2016.12.002","article-title":"Adherence to fixed-combination versus unfixed travoprost 0.004%\/timolol 0.5% for glaucoma or ocular hypertension: a randomized trial","volume":"176","author":"Barnebey","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib19","unstructured":"Allergan plc. Ganfort [package leaflet]. Available at: https:\/\/allergan-web-cdn-prod.azureedge.net\/allerganindia\/allerganindia\/media\/allergan-india\/products\/ganfort.pdf. Accessed January 11, 2020."},{"key":"10.1016\/j.clinthera.2019.12.008_bib20","unstructured":"Allergan plc. Combigan (brimonidine tartrate\/timolol maleate ophthalmic solution) 0.2%\/0.5% [prescribing information highlights]. Available at: http:\/\/www.allergan.com\/assets\/pdf\/combigan_pi.pdf. Accessed January 11, 2020."},{"key":"10.1016\/j.clinthera.2019.12.008_bib21","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0161-6420(98)91046-6","article-title":"A\u00a0randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide","volume":"105","author":"Boyle","year":"1998","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2019.12.008_bib22","unstructured":"Merck & Co, Inc. Trusopt (dorzolamide hydrochloride ophthalmic solution) 2% [highlights of prescribing information]. Available at: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/t\/trusopt\/trusopt_pi.pdf. Accessed January 11, 2020."},{"key":"10.1016\/j.clinthera.2019.12.008_bib23","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2147\/OPTH.S143428","article-title":"Ocular pharmacokinetics and safety of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications","volume":"11","author":"Shen","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib24","first-page":"4586763","article-title":"A\u00a0masked, randomized, phase 3 comparison of triple fixed combination bimatoprost\/brimonidine\/timolol versus fixed combination brimonidine\/timolol for lowering intraocular pressure","volume":"2017","author":"Hartleben-Matkin","year":"2017","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib25","first-page":"174","article-title":"The efficacy and safety of two fixed combinations: timolol-dorzolamide-brimonidine versus timolol-dorzolamide. A prospective, randomized, double-masked, multi-center, 6-month clinical trial","volume":"41","author":"Baiza-Duran","year":"2009","journal-title":"Ann Ophthalmol (Skokie)"},{"key":"10.1016\/j.clinthera.2019.12.008_bib26","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2147\/OPTH.S33578","article-title":"Comparison of timolol 0.5%\u00a0+ brimonidine 0.2%\u00a0+ dorzolamide 2% versus timolol 0.5%\u00a0+ brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension","volume":"6","author":"Baiza-Duran","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/112067210701700311","article-title":"Ocular symptoms and signs with preserved and preservative-free glaucoma medications","volume":"17","author":"Jaenen","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib28","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1755-3768.2008.01250.x","article-title":"Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma","volume":"86","author":"Baudouin","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib29","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","article-title":"Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension\u2013an evidence-based review","volume":"112","author":"Olthoff","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2019.12.008_bib30","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/OPX.0000000000000009","article-title":"Glaucoma medication adherence among African Americans: program development","volume":"90","author":"Dreer","year":"2013","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.clinthera.2019.12.008_bib31","first-page":"497","article-title":"Relationship between compliance and background factors of glaucoma patients [in Japanese]","volume":"110","author":"Ikushima","year":"2006","journal-title":"Nippon Ganka Gakkai Zasshi"},{"key":"10.1016\/j.clinthera.2019.12.008_bib32","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.ophtha.2015.03.026","article-title":"The most common barriers to glaucoma medication adherence: a cross-sectional survey","volume":"122","author":"Newman Casey","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2019.12.008_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2415-10-1","article-title":"Scoring and psychometric properties of the Eye-Drop Satisfaction Questionnaire (EDSQ), an instrument to assess satisfaction and compliance with glaucoma treatment","volume":"10","author":"Regnault","year":"2010","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib34","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ajo.2007.06.012","article-title":"Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use","volume":"144","author":"Robin","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib35","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ophtha.2004.12.026","article-title":"Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?","volume":"112","author":"Robin","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2019.12.008_bib36","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0161-6420(01)00584-X","article-title":"Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated\u00a0IOP: a 3-month clinical trial","volume":"108","author":"Brandt","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2019.12.008_bib37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/BF02850299","article-title":"Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension","volume":"18","author":"Gandolfi","year":"2001","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2019.12.008_bib38","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/archopht.120.10.1286","article-title":"One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension","volume":"120","author":"Higginbotham","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0002-9394(02)01827-5","article-title":"A\u00a0six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma","volume":"135","author":"Noecker","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib40","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0002-9394(03)00098-9","article-title":"A\u00a0comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study","volume":"135","author":"Parrish","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2019.12.008_bib41","doi-asserted-by":"crossref","first-page":"S361","DOI":"10.1016\/S0039-6257(01)00219-3","article-title":"Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure","volume":"45","author":"Sherwood","year":"2001","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib42","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2147\/OPTH.S17457","article-title":"Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials","volume":"5","author":"Wirta","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib43","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2)","volume":"186","author":"Serle","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib44","unstructured":"Bacharach J, Holland E, Sheng H, et\u00a0al. Pooled safety analysis of a once-daily fixed-dose combination (FDC) of netasurdil 0.02% and latanoprost 0.005% in ocular hypertension (OHT) and open-angle glaucoma (OAG). European Glaucoma Society 13th Congress. Florence, Italy: 2018. Available at: https:\/\/www.egs2018.org\/sites\/www.egs2018.org\/files\/documenti\/egs2018-abstract-book.pdf. Accessed January 11, 2020."},{"key":"10.1016\/j.clinthera.2019.12.008_bib45","unstructured":"Aerie Pharmaceuticals Inc. Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%\/0.005% [highlights of prescribing information]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208259s000lbl.pdf. Accessed January 11, 2020."},{"key":"10.1016\/j.clinthera.2019.12.008_bib46","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.2042-7158.1995.tb06726.x","article-title":"Ophthalmic preservatives as absorption promoters for ocular drug delivery","volume":"47","author":"Sasaki","year":"1995","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2016.01.053","article-title":"Understanding the influence of surface properties of nanoparticles and penetration enhancers for improving bioavailability in eye tissues in\u00a0vivo","volume":"501","author":"Mahaling","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.clinthera.2019.12.008_bib48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejpb.2016.07.009","article-title":"Effect of pH and penetration enhancers on cysteamine stability and trans-corneal transport","volume":"107","author":"Pescina","year":"2016","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.clinthera.2019.12.008_bib49","unstructured":"European Medicines Agency. Assessment report for Lumigan (January 2010). Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000391\/WC500074096.pdf. Accessed January 11, 2020."},{"key":"10.1016\/j.clinthera.2019.12.008_bib50","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archopht.119.7.994","article-title":"Comparison of the ocular hypotensive lipid AGN 192024 with timolol: dosing, efficacy, and safety evaluation of a novel compound for glaucoma management","volume":"119","author":"Laibovitz","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2019.12.008_bib51","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ajo.2009.12.003","article-title":"Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension","volume":"149","author":"Katz","year":"2010","journal-title":"Am J Ophthalmol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:52:06Z","timestamp":1758963126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819305922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0149291819305922"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.12.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fixed-combination Bimatoprost\/Brimonidine\/Timolol in Glaucoma: A Randomized, Masked, Controlled, Phase III Study Conducted in Brazil\u2606","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}